StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
009300.KQ$13500.00-6.96%
Fair $13500.00+0.0%

009300.KQ

Sam-A Pharm. Co., Ltd

Unknown / UnknownKOSDAQ

$13500.00

-1010.00 (-6.96%)

Fairly Valued+0.0%Fair Value $13500.00Fund rank 36/100 · Data gapFallback financials|
SA 37/D
F-Score: 3/9
Declining Revenue

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $16.9B · quality 78.0/100

Data gap 36/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 74/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

37/100

D

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Revenue has declined for 2 consecutive years
Thesis & Journal · 009300.KQLocal privado en este navegador · Sam-A Pharm. Co., Ltd
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$82.4B

P/E

6.4x

↓

EV/EBITDA

3.9x

↓

ROE

5.7%

↑

Gross Margin

59.6%

↑

Debt/Equity

0.03

↓
52-Week Range$13500
$13490$19250

TradingView lightweight chart

009300.KQ price, volumen y niveles de valoración

Último $13,500Periodo +75.6%
Fair value: $13,500

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-1.6%

FCF CAGR

-22.7%

FCF margin

11.5%

FCF / Net income

0.69x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $77.80B · net income $12.94B · FCF $8.94B

2022-FY → 2025-FY

Gross margin

59.6%-1.8% pts

Operating margin

14.1%-8.2% pts

Net margin

16.6%+2.1% pts

FCF margin

11.5%-12.2% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$77.80B$77.80B$95.58B$97.21B$81.70B
Net Income$12.94B$12.94B$22.08B$21.37B$11.91B
EBITDA$21.28B$21.28B$34.07B$32.59B$21.65B
EPS2120.002120.003618.003502.001952.00
Gross Margin59.6%59.6%63.6%63.4%61.4%
Operating Margin14.1%14.1%25.6%24.2%22.3%
Net Margin16.6%16.6%23.1%22.0%14.6%
Balance Sheet
Debt/Equity0.030.030.060.060.01
Cash Flow
Free Cash Flow$8.94B$8.94B$18.74B$16.94B$19.37B
Returns
ROE5.7%5.7%10.0%10.7%6.6%
Valuation
P/E6.376.374.774.628.68
EV/EBITDA3.893.893.193.114.44
P/B0.360.360.480.490.57
Growth & Yield
Revenue Growth-18.6%-18.6%-1.7%19.0%—
EPS Growth-41.4%-41.4%3.3%79.4%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-17.3%

fácil

EPS terminal req.

$1197.90

Spread vs growth

-24.1%

5Y implied EPS CAGR

-7.3%

fácil

EPS terminal req.

$1449.46

Spread vs growth

-34.1%

10Y implied EPS CAGR

1.0%

fácil

EPS terminal req.

$2334.37

Spread vs growth

-42.4%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -20.5%

Total return

-20.5%

Start / end P/E

4.7x → 6.4x

EPS bridge

3618.00 → 2120.00

Residual

-14.7%

EPS growth-41.4%
Multiple rerating+35.6%
Dividend+0.0%
Residual / FX / buybacks / cross-term-14.7%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.